drugset / Trial / NCT00739414

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

NCT00739414

Phase 1 Completed 14 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will characterize the safety, tolerability, biological activity, and pharmacokinetics of LBH589 in Japanese patients with advanced solid tumors whose disease has progressed despite standard therapies, or for whom no standard therapy exists.

Timeline

Start
2008-07
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 10 mg/m2 Intravenous
Subject Panobinostat Small molecule 15 mg/m2 Intravenous
Subject Panobinostat Small molecule 20 mg/m2 Intravenous

Indications